Figure 4: Changes in body weight in A) lean mice and B) obese mice and changes in food intake in C) lean mice and D) obese mice, across the three different experimental treatment groups
The investigational immuno-oncology combination of efti and KEYTRUDA achieved an objective response rate (ORR) of 35.5% (11 of 31 evaluable patients) and a disease control rate (DCR) of 58.1%, according to RECIST 1.1, in 1L HNSCC patients whose tumors do not express PD-L1 (Combined Positive Score [CPS] 20 PD-L1 expression levels are approximately 20%, 30%, and 50% of the HNSCC patient population, respectively
According to a statement provided by the company, "Our CEO Mike Doustdar and EVP, US Operations, Dave Moore were the only two Novo Nordisk representatives in the Oval Office yesterday." Another statement from the company read, "Online speculation led to several media reports incorrectly identifying Gordon Findlay, a Novo Nordisk employee, as the individual at the event
Pan Y, Hui X, Hoo RLC, Ye D, Chan CYC, Feng T, et al
